Medication-overuse headache (MOH) is one of the most common chronic headaches with a prevalence of 1–2% in the general population.1–3 The International Classification of Headache Disorders (ICHD) describes MOH as a:
‘... headache occurring on 15 or more days per month developing as a consequence of regular overuse of acute or symptomatic headache medication (on 10 or more, or 15 or more days per month, depending on the medication) for more than 3 months. It usually, but not invariably, resolves after the overuse is stopped’.4
Medication causing the symptoms could be regular analgesics, ergotamines, triptans, opioids, or a combination of medications.
MOH is a heterogeneous disorder, which has been suggested to include subgroups with simple medication overuse as well as complex cases with more ‘dependency-like’ behaviour.5–7 Research suggests that individuals with a ‘problem-solving mode’ with low acceptance of pain are more prone to developing MOH.8 In the general population, MOH can be identified through screening for headache frequency, followed by a short screening instrument for behavioural dependence, the Severity of Dependence Scale (SDS).9 Most MOH patients have consulted their GP for headache.10 It is well established that withdrawal of the overused medication in most cases leads to improvement of the headache, but treatment is challenging and varies from simple advice to lengthy in-hospital treatments.1,11 Patient education is an important part of the management of patients with MOH, and early recognition of patients with MOH and patients at risk for MOH is recommended as a clinical strategy.11,12
Screening and brief intervention (BI) is a well-known approach to identify and treat overuse of alcohol and other addictive drugs.13–15 BI involves the use of an identification tool followed by feedback to the identified individual as being ‘at risk’. The final step is to give information suggesting reduction of the use of the particular substance. A review identified several barriers to implementation of screening and BI for alcohol problems in general practice, such as lack of time, resources, and training. Context and timing was also an issue.16 Although there is a considerable amount of research exploring screening and BI for alcohol overuse,16 there are no previous studies on GPs’ experiences using BI for MOH. Studies of factors that influenced GPs’ views on screening and BI for alcohol problems in Denmark and Norway found that integration of screening and BI into existing routines could be difficult, and that screening and BI could represent a challenge to the relationship between the GP and patient.17,18
In the Brief Intervention for Medication-Overuse Headache (BIMOH) study, BI was adopted for managing MOH in general practice, and a pragmatic cluster-randomised controlled trial (RCT) was conducted to test BI against business as usual (Box 1).19
Box 1. The Brief Intervention for Medication-Overuse Headache (BIMOH) study
The study was a double-blind, pragmatic cluster randomised parallel controlled trial in primary care in Norway. Outcomes were based on interviews with patients who were assessed 3 and 6 months after the intervention. The participating GPs received a 1-day course held by headache specialists. Patients recruited by screening of participating GPs' patient lists were cluster randomised and received treatment by their GP. A total of 25 486 patients were screened, responder rate was 42%, A random sample of 104 who screened positive for possible MOH were invited, 73 of these participated. GPs in half of the continuous medical education (CME) groups received the BI course initially and used BI to manage their own patients, while the others ran their clinical business as usual (BAU). After 6 months, the GPs in the BAU group also received the BI course as a part of the design and thereafter applied the BI to their listed patients (initially BAU group). The BI method consisted of GPs first evaluating their MOH patients using the Severity of Dependence Scale. Based on this, the patients received feedback about the personal risk of MOH, and recommendations for reducing intake of headache medication. In all, 18 CME groups were invited, of whom three CME groups did not respond to the invitation and five groups declined participation. Thus, 10 CME groups with 50 GPs were included. Based on national figures the included GPs were representative in terms of practice localisation (urban versus suburban) and age distribution, but there were more female GPs among participants in the sample.
How this fits in
Medication-overuse headache (MOH) is a cause of chronic headache in the general population, but structured, evidence-based instruments for handling MOH have not, so far, been generally available. Brief intervention (BI) may be such an instrument. This study suggests that GPs experience BI as a feasible strategy to treat MOH in general practice. The results underscore that using BI requires a good alliance between the doctor and patient, and GPs must be prepared to invest effort into countering patients’ misconceptions about medication.
Results from the study suggest that BI performed by GPs, after a 1-day training course, reduces headache days and medication use in patients with MOH.20